US stocks surged on Wednesday, fueled by a slowdown in core inflation and better-than-expected earnings from major banks. The ...

TD Cowen analyst Steve Scala reiterated a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $900.00.Stay ...

The Dow, S&P 500, and Nasdaq are rallying Wednesday as the stock market digests the latest CPI inflation report and earnings from several big U.S. banks.

Eli Lilly trims Q4 guidance but maintains optimism with promising drugs like Zepbound for sleep apnea and global launches ...

EDWARDSVILLE - Metro-East Lutheran High School Metro-East Lutheran High School Second Quarter Honor Roll 2024-2025 The ...

Eli Lilly's stock dipped due to cutting Q4 sales targets, despite a strong 2024 performance from Mounjaro and Zepbound. Click ...

Shares of several obesity drugmakers dip after LLY lowered its revenue outlook for 2024 amid slower-than-expected sales ...

Eli Lilly forecasts $45 billion revenue for 2024, 32% higher than last year. Medicare changes and stocking issues impact the revised guidance.

Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...

Sales results disclosed Tuesday raised concern that investors may have overestimated the demand for Zepbound and Mounjaro.

The FTSE 100 ( ^FTSE) and European stocks gained on Wednesday as traders digested news that UK inflation unexpectedly fell to ...

Eli Lilly & Co. (LLY) shares rose 0.3% premarket Wednesday, bouncing slightly after Tuesday's steep 6% plunge — the worst ...